Drug Profile
Opicinumab - Biogen
Alternative Names: Anti-LINGO 1; Anti-LINGO-1 antibody; BIIB-033Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec; Dyax
- Developer Biogen
- Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Neuropsychotherapeutics
- Mechanism of Action Cell differentiation stimulants; LINGO 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Optic neuritis
Most Recent Events
- 13 Oct 2021 Safety and efficacy data from the phase II AFFINITY trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
- 01 Mar 2021 Biogen terminates the phase II AFFINITY trial for Multiple sclerosis (Adjunctive treatment) as it fails to achieve its primary and secondary endpoints in Australia, Belgium, Canada, Czech Republic, France, Germany, Switzerland, Netherlands, Poland, Spain, Hungary, Italy, United Kingdom (IV) (NCT03222973)
- 21 Oct 2020 Discontinued - Phase-II for Multiple sclerosis in European Union, USA, United Kingdom, Canada (IV), and Multiple sclerosis (Adjunctive treatment) in European Union, USA, Australia (IV) in October 2020